SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Grandy who wrote (543)3/29/1997 7:52:00 AM
From: Trey Yon   of 6136
 
AGPH has competion coming from Vertex Pharm & their partner Glaxo.
On 2/19/97 VRTX said they will announced Phase III trials for children with AIDS in a few weeks. This won't help AGPH over the short haul. Analyst's expect the Vertex/Glaxo drug VX478 to be ready for market around Q2 1998. I read that Viracept will be priced around $5,000 for a year's supply. I think Merk has been getting around $12,000 for a year's supply of Crixavan. The new prescription data for Viracept show start coming out next week and a clearer picture of how much market share AGPH is gaining from Merk will probably begin to emerge by Mid April. Agouron's chart will tell the tale for all to see this month.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News